2012-10-11 16:40:11 -
A number of stocks were upgraded and downgraded by equities research analysts
today, as reported by Analyst Ratings Network ( bit.ly/equitybriefdaily)
and Equity Brief:
BTIG Research initiated coverage on shares of Rite Aid (RAD). They issued a buy
rating on the stock and set a $2.25 price target.
Zacks downgraded shares of Regeneron Pharms (REGN) from an outperform rating to
a neutral rating. Their analysts now have a $160.00 price target on the stock.
Zacks' analyst wrote, "Regeneron Pharmaceuticals' second quarter 2012 adjusted
earnings of $0.71 per share blew past the Zacks Consensus Estimate of $0.25.
Higher revenues, driven by strong sales of eye drug, Eylea, boosted earnings in
the second quarter of 2012. Encouraged by the strong performance of Eylea, the
company increased its forecast for 2012 US Eylea sales
for the second successive
quarter. The label expansion of Eylea in the US into the CRVO indication has
further boosted its sales potential. Moreover, the US approval of oncology drug,
Zaltrap, is another positive for Regeneron. However, we believe the current
price reflects all the positive news and are reverting to a Neutral
recommendation on the stock."
RBC Capital upgraded shares of RLJ Lodging Trust (RLJ) from a sector perform
rating to an outperform rating. RBC Capital now has a $21.00 price target on the
stock, up previously from $20.00.
MKM Partners downgraded shares of The Ryland Group, Inc. (RYL) from a buy rating
to a sell rating.
Barclays Capital downgraded shares of SAP Aktiengesellschaft (SAP) from an
overweight rating to an equal weight rating. Their analysts now have a $70.00
price target on the stock.
Stay on top of analysts' coverage with Analyst Ratings Network's free daily
email newsletter that provides a concise list of analysts' upgrades, downgrades
and initiations. Register at bit.ly/equitybriefdaily
Content and Media Contact: firstname.lastname@example.org
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Brief via Thomson Reuters ONE